Melián C, Peterson M E
Department of Medicine, Animal Medical Center, New York, New York 10021, USA.
J Small Anim Pract. 1996 Jun;37(6):268-75. doi: 10.1111/j.1748-5827.1996.tb02377.x.
Hypoadrenocorticism was diagnosed in 42 dogs over a two-and-a-half-year period. The disease occurred more commonly in young to middle-aged dogs, with a female:male ratio of 2:1. Most dogs had chronic intermittent signs (eg, poor appetite, lethargy and vomiting), but more than a third were in acute adrenal crisis at the time of diagnosis. Serum biochemical testing revealed azotaemia, hyperphosphataemia, hyperkalaemia and hyponatraemia in almost all the dogs. In all dogs, results of adrenocorticotrophic hormone (ACTH) stimulation testing revealed a low to low-normal serum baseline cortisol concentration that failed to increase after ACTH administration. In two dogs with persistently normal serum electrolytes concentration, one had a markedly high plasma ACTH concentration diagnostic for primary hypoadrenocorticism, whereas the other had a low concentration confirming secondary hypoadrenocorticism. Fludrocortisone acetate was initially used for mineralocorticoid replacement in 33 of the 37 treated dogs with primary hypoadrenocorticism (final median dosage, 27.0 micrograms/kg/day), but supplementation was changed to desoxycorticosterone pivalate (DOCP) in four dogs because of poor response or adverse effects. Seven dogs with primary hypoadrenocorticism were treated with DOCP (final median dosage, 2.02 mg/kg/month). Prednisone, initially administered to 36 dogs, was discontinued in 11 dogs because of side effects. Of the dogs treated with fludrocortisone, the response was considered good to excellent in 26 dogs (78.8 per cent), fair in three, and poor in four. All dogs treated with DOCP responded well.
在两年半的时间里,42只犬被诊断为肾上腺皮质功能减退症。该病在青年至中年犬中更为常见,雌雄性别比为2:1。大多数犬有慢性间歇性症状(如食欲不振、嗜睡和呕吐),但超过三分之一的犬在诊断时处于急性肾上腺危象。血清生化检测显示,几乎所有犬都有氮血症、高磷血症、高钾血症和低钠血症。在所有犬中,促肾上腺皮质激素(ACTH)刺激试验结果显示血清基础皮质醇浓度低至低正常,注射ACTH后未能升高。在两只血清电解质浓度持续正常的犬中,一只血浆ACTH浓度明显升高,诊断为原发性肾上腺皮质功能减退症,而另一只浓度较低,确诊为继发性肾上腺皮质功能减退症。37只接受治疗的原发性肾上腺皮质功能减退症犬中,33只最初使用醋酸氟氢可的松进行盐皮质激素替代治疗(最终中位剂量,27.0微克/千克/天),但由于反应不佳或出现不良反应,4只犬的替代治疗改为使用特戊酸去氧皮质酮(DOCP)。7只原发性肾上腺皮质功能减退症犬接受了DOCP治疗(最终中位剂量,2.02毫克/千克/月)。最初对36只犬使用泼尼松治疗,11只犬因出现副作用而停药。在接受醋酸氟氢可的松治疗的犬中,26只犬(78.8%)的反应被认为良好至优秀,3只犬反应一般,4只犬反应较差。所有接受DOCP治疗的犬反应良好。